Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Profound Medical ( (TSE:PRN) ) is now available.
Profound Medical reported record fourth-quarter 2025 revenue of $6.0 million, up 43% year over year, driven by growing adoption of its TULSA-PRO system, which now has an installed base of 78 sites and a qualified pipeline of 110 additional systems, with management expecting about 120 installs by the end of 2026. The company highlighted broad real-world use of TULSA-PRO across prostate cancer and benign prostatic hyperplasia cases, new clinical data from leading centers, and the launch of its TULSA-AI Volume Reduction module, which it believes could triple its addressable prostate disease market to roughly 600,000 patients annually.
Profound also advanced its global commercial strategy by regaining exclusive TULSA-PRO distribution rights in Canada and signing distribution agreements in Saudi Arabia, Australia, and New Zealand, while a milestone at the Hong Center Scottsdale underscored growing urologist-led adoption. In December 2025, the company strengthened its balance sheet with more than $42 million in new equity financing from healthcare-focused and existing investors, supporting its commercial expansion and positioning it to compete more aggressively in the prostate therapy market.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company focused on interventional MRI procedures for prostate and other diseases, led by its TULSA-PRO and Sonalleve technologies. The company targets hospitals and specialized treatment centers worldwide, and is expanding its presence through a direct sales force in North America and strategic distribution partnerships in key international markets.
Average Trading Volume: 17,055
Technical Sentiment Signal: Buy
Current Market Cap: C$368M
See more data about PRN stock on TipRanks’ Stock Analysis page.